Qiagen and GATC Biotech partner to analyse disease-focused genetic data

QIAGEN signed a commercial agreement with GATC Biotech to provide GATC clients full access to QIAGEN’s Ingenuity Variant Analysis solution for analysis and interpretation of genetic data. 

GATC is one of Europe’s leading providers of DNA and RNA sequencing services to customers worldwide. The access will take the form of interpretation services and direct access to Ingenuity Variant Analysis as a feature of the GATC Biotech’s services.  Ingenuity Variant Analysis is a powerful bioinformatics platform enabling laboratories to efficiently evaluate data generated by high-throughput next-generation sequencing (NGS) technologies. The QIAGEN software quickly filters genetic variants in a secure, private cloud-based environment to identify variants most likely to cause disease, drawing upon the industry-leading Ingenuity Knowledge Base. 

Dr. Marcus Benz, Chief Operating Officer of GATC Biotech, commented: “This new commercial agreement with QIAGEN provides our customers with full access to the Ingenuity software enabling rapid analysis and interpretation of next-generation sequencing data in  terms of relevant genetic variations. We are offering our clients a unique, fully integrated one-stop solution. GATC Biotech selected the Ingenuity Variant Analysis solution as a perfect match. Integrating this software tool with our InView Human Exome product enables us to provide world-class data analysis for end-users of NGS, including clinical and laboratory geneticists and other professionals investigating diseases.”

The agreement with GATC Biotech is non-exclusive, and financial terms were not disclosed. Great news for Qiagen following last acquisition of Enzymatics to lead the Next-gen sequencing field.

Of course, Qiagen and GATC are also present on our LabiotechMap

Previous post

Syngenta corn trait expansion further continues thanks the Vietnamese approval

Next post

Evaluation of recommendations on the vaccination schedules in a set of European Countries

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.